Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.83 USD
-0.05 (-0.42%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $11.48 -0.35 (-2.96%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVTX 11.83 -0.05(-0.42%)
Will AVTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AVTX
Is AVTX preparing to trend higher? MACD Bullish Signal Line Cross shows up after slipping 0.42%
AVTX forms Pocket Pivot on September 19
Crossed Above 20 Day Moving Average appears for AVTX after 16.09% move
Oppenheimer Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)
AVTX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | AVTX Stock News